Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05893927|
Recruitment Status : Not yet recruiting
First Posted : June 8, 2023
Last Update Posted : August 24, 2023
The goal of this clinical trial is to evaluate the use and effectiveness of a mobile web application (app) that is designed to educate and allow patients to manage diabetes and make sustainable lifestyle changes, and to study the impact of the app on clinical outcomes of diabetes (HA1C) and educational outcomes (Self-Efficacy for Diabetes Scale). The main question to answer is: Does the use of the Diabetes Application significantly affect clinical outcomes of diabetes and cardiometabolic risk factors (BMI and Blood Pressure)? Patients will be enrolled in one of two available arms of the study.
Participants in the 'intervention arm' will use the app to view educational information presented as videos in the following areas: Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes and Disease Pathophysiology. They will continue routine follow-up care with their primary care physicians during the study.
Participants in the 'control arm' will continue with their primary care physician in routine follow-up care, as normally scheduled.
Researchers will compare the intervention arm participants to the control arm participants to find out about and compare changes in HA1C, systolic blood pressure, diastolic blood pressure, and body mass index. Groups will also be compared on the basis of self-perceived confidence of managing their diabetes by way of the Diabetes Self Efficacy Scale.
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2 Diabetes Education Lifestyle Modification||Other: Diabetes education web site application||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Participants will be recruited to participate in the study, and then randomized to one of two arms.|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Evaluating the Clinical Impact of a PCP Developed Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes|
|Estimated Study Start Date :||September 15, 2023|
|Estimated Primary Completion Date :||September 30, 2025|
|Estimated Study Completion Date :||September 30, 2025|
Experimental: Intervention arm
Participants enrolled in the intervention arm will be given a 6-month access period to the diabetes education application designed by the study team. The web site will offer videos related to a specific areas of education concerning diabetes self-management. To encourage compliance, participant users will receive weekly notifications from the application that will guide them through viewing all videos in the series. Participants will continue routine follow-up appointments with their primary care physicians during the study period. There will be no restrictions on starting or stopping medications during the study period.
Other: Diabetes education web site application
The Diabetes education website application will contain informational videos for this protocol. The videos will include a welcome video and the categorical topics of Healthy Coping, Healthy Eating, Staying Active, Medications (Use and Safety), Problem Solving in Diabetes, and Disease Pathophysiology. Each category contains several videos providing education about a different component of diabetes care.
No Intervention: Control arm
Participants in the control arm will not have access to the Diabetes Application. They will continue follow-up appointments according to the standard of care with their primary care physician, diabetic educators, etc. There are no restrictions on starting or stopping medications for patients within the control arm.
- Hemoglobin A1c [ Time Frame: 6 months ]Blood Test
- "Self-Efficacy for Diabetes Scale" [ Time Frame: 6 months ]A validated (free to use) survey that examines self-perceived ability to manage diabetes. Scores are reported on a scale from 1-10. 1 reflecting Not at all confident and 10 reflecting confident. The minimum total value is 8, and the maximum value is 80. A higher score indicates that the individual has a better outcome, i.e., more confident that he/she can perform the task regularly at the present time.
- Body Mass Index [ Time Frame: 6 months ]Height-to-weight ratio, an indicator of underweight, normal weight, or overweight/obese
- Blood pressure [ Time Frame: 6 months ]Systolic and Diastolic
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05893927
|Contact: Mary E Alderfer, MSNemail@example.com|
|Contact: Pamela Marrerofirstname.lastname@example.org|
|United States, Pennsylvania|
|Reading Hospital, an affiliate of Tower Health|
|West Reading, Pennsylvania, United States, 19611|
|Contact: Research coordinator 484-628-8585 email@example.com|
|Principal Investigator: Luis A Murillo, MD, MPH|
|Sub-Investigator: Sally Snyder, MSN|
|Principal Investigator:||Luis A Murillo, MD, MPH||Reading Hospital Tower Health|